Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207255 · ClinicalTrials.gov registry record · Phase 2
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT04207255 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 69 participants.
The verdict
NCT04207255, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a Phase II study of the investigational drug opaganib. Patients with metastatic castration resistant prostate cancer (mCRPC) who have experienced disease progression while receiving abiraterone or enzalutamide will receive Opaganib at either 250 mg or 500 mg by mouth twice a day continuously. Patients will continue on study drug until the development of progressive disease, intolerable toxicity, withdrawal of patient consent or other event as outlined in patient discontinuation.
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Opaganib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2020-03-27 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04207255
The ClinicalTrials.gov registry entry for NCT04207255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT04207255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04207255 about?
NCT04207255 is a clinical study titled "Addition of Opaganib to Androgen Antagonists in Patients With mCRPC". This is a Phase II study of the investigational drug opaganib. Patients with metastatic castration resistant prostate cancer (mCRPC) who have experienced disease progression while receiving abiraterone or enzalutamide will receive Opaganib at either 250 mg or 500 mg by mouth twice a day continuously...
What is the current status of trial NCT04207255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2020-03-27. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT04207255?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Opaganib (DRUG).
Who is sponsoring clinical trial NCT04207255?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.